351 related articles for article (PubMed ID: 32457760)
1. Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells.
McNerney KO; Karageorgos SA; Hogarty MD; Bassiri H
Front Immunol; 2020; 11():873. PubMed ID: 32457760
[TBL] [Abstract][Full Text] [Related]
2. Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing.
Belounis A; Ayoub M; Cordeiro P; Lemieux W; Teira P; Haddad E; Herblot S; Duval M
Cancer Immunol Immunother; 2020 Sep; 69(9):1767-1779. PubMed ID: 32342128
[TBL] [Abstract][Full Text] [Related]
3. Antibody-dependent cellular cytotoxicity toward neuroblastoma enhanced by activated invariant natural killer T cells.
Mise N; Takami M; Suzuki A; Kamata T; Harada K; Hishiki T; Saito T; Terui K; Mitsunaga T; Nakata M; Ikeuchi T; Nakayama T; Yoshida H; Motohashi S
Cancer Sci; 2016 Mar; 107(3):233-41. PubMed ID: 26749374
[TBL] [Abstract][Full Text] [Related]
4. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
5. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma Cell Lines Are Refractory to Genotoxic Drug-Mediated Induction of Ligands for NK Cell-Activating Receptors.
Veneziani I; Brandetti E; Ognibene M; Pezzolo A; Pistoia V; Cifaldi L
J Immunol Res; 2018; 2018():4972410. PubMed ID: 29805983
[TBL] [Abstract][Full Text] [Related]
7. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
Front Immunol; 2019; 10():2816. PubMed ID: 31849984
[TBL] [Abstract][Full Text] [Related]
8. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
9. Invariant natural killer T cells in immune surveillance and tumor immunotherapy: perspectives and potentials.
Haeryfar SM
Arch Iran Med; 2008 Mar; 11(2):186-95. PubMed ID: 18298297
[TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
[TBL] [Abstract][Full Text] [Related]
11. Monocyte and Macrophage in Neuroblastoma: Blocking Their Pro-Tumoral Functions and Strengthening Their Crosstalk with Natural Killer Cells.
Vitale C; Bottino C; Castriconi R
Cells; 2023 Mar; 12(6):. PubMed ID: 36980226
[TBL] [Abstract][Full Text] [Related]
12. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
13. Characterizing porcine invariant natural killer T cells: A comparative study with NK cells and T cells.
Yang G; Artiaga BL; Lewis ST; Driver JP
Dev Comp Immunol; 2017 Nov; 76():343-351. PubMed ID: 28694168
[TBL] [Abstract][Full Text] [Related]
14. NK cell-based immunotherapy for cancer.
Fang F; Xiao W; Tian Z
Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
[TBL] [Abstract][Full Text] [Related]
15. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice.
Castriconi R; Dondero A; Cilli M; Ognio E; Pezzolo A; De Giovanni B; Gambini C; Pistoia V; Moretta L; Moretta A; Corrias MV
Cancer Immunol Immunother; 2007 Nov; 56(11):1733-42. PubMed ID: 17426969
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice.
Kozlowska AK; Kaur K; Topchyan P; Jewett A
Cancer Immunol Immunother; 2016 Jul; 65(7):835-45. PubMed ID: 27034236
[TBL] [Abstract][Full Text] [Related]
17. Leveraging natural killer cells for cancer immunotherapy.
Grossenbacher SK; Aguilar EG; Murphy WJ
Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
[TBL] [Abstract][Full Text] [Related]
18. T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.
Das R
Crit Rev Oncog; 2024; 29(1):69-81. PubMed ID: 38421715
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo-activated MHC-unrestricted immune effectors for cancer adoptive immunotherapy.
Leuci V; Mesiano G; Gammaitoni L; Todorovic M; Giraudo L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Anticancer Agents Med Chem; 2014 Feb; 14(2):211-22. PubMed ID: 24237224
[TBL] [Abstract][Full Text] [Related]
20. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
